IL5 and chronic obstructive pulmonary disease: However, the response to anti‐IL5 and IL‐5R monoclonal antibodies in COPD has been disappointing with benefits related to the intensity of the blood eosinophil count as seen in asthma but the magnitude of response greatly reduced.2, 32, 33, 34 Thus, both the epithelial gene expression profile and response to T2‐directed biological therapies differ between eosinophilic asthma and COPD.